Abstract
Background: We previously identified a four-generation family with medullary thyroid cancer (MTC) and a germline p.Y791 F RET mutation whose cancer lacked a strong genotype-phenotype correlation. The entire gene coding region of the RET gene should be sequenced when genotype-phenotype discrepancies are observed in patients with multiple endocrine neoplasia type 2 (MEN 2), even if a RET hotspot mutation has been identified. Methods: A new genetic test was performed in the index case of this family with the p.Y791F RET germline mutation. The entire coding region of the RET gene was investigated by direct sequencing of PCR products. Once a mutation was identified, the target exon was sequenced in all at-risk relatives. Results: An additional p.C634Y germline mutation in the RET gene was identified in the reported family. The double mutation occurred in cis and segregated with the phenotype. Through the Brazilian Genetic Screening Program developed at our institution, we additionally report the combination of these two mutations (p.C634Y/p.Y791F) in the RET gene in four other unrelated families. The overall penetrance of MTC and pheochromocytoma in patients with the p.C634Y/p.Y791 F mutations was 79% and 13%, respectively. Conclusion: Our data emphasises that a comprehensive analysis of the RET gene may reveal multiple germline mutations in MEN 2 patients who exhibit an atypical clinical course of the disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology 2004, 145: 5448–51.
Castellone MD, Verrienti A, Magendra Rao D, et al. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization. Clin Endocrinol (Oxf) 2010, 73: 529–34.
Muzza M, Cordella D, Bombled J, et al. Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro. Eur J Endocrinol 2010, 162: 771–7.
Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19: 565–612.
Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007, 92: 4725–9.
Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996, 276: 1575–9.
Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of M EN type 1 and type 2. J Clin Endocrinol Metab 2001, 86: 5658–71.
Berndt I, Reuter M, Saller B, et al. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998, 83: 770–4.
Vaclavikova E, Dvorakova S, Sykorova V, et al. RET mutation Tyr791 Phe: the genetic cause of different diseases derived from neural crest. Endocrine 2009, 36: 419–24.
Arum SM, Dahia PL, Schneider K, Braverman LE. A RET mutation with decreased penetrance in the family of a patient with a “sporadic” pheochromocytoma. Endocrine 2005, 28: 193–8.
Brauer VF, Scholz GH, Neumann S, et al. RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed? Endocr Pract 2004, 10: 5–9.
Fitze G, Schierz M, Bredow J, et al. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann Surg 2002, 236: 570–5.
Erlic Z, Hoffmann MM, Sullivan M, et al. Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. J Clin Endocrinol Metab 2010, 95: 308–13.
Toledo RA, Wagner SM, Coutinho FL, et al. High penetrance of pheochromocytoma associated with the novel C634Y/Y791 F double germline mutation in the RET protooncogene. J Clin Endocrinol Metab 2010, 95: 1318–27.
Dvorakova S, Vaclavikova E, Ryska A, et al. Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds. ExpClin Endocrinol Diabetes 2006, 114: 192–6.
Tamanaha R, Camacho CP, Ikejiri ES, Maciel RM, Cerutti JM. Y791F RET mutation and early onset of medullary thyroid carcinoma in a Brazilian kindred: evaluation of phenotype-modifying effect of germline variants. Clin Endocrinol (Oxf) 2007, 67: 806–8.
Tamanaha R, Camacho CP, Pereira AC, et al. Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation. Clin Endocrinol (Oxf) 2009, 71: 56–64.
Hemerly JP, Bastos AU, Cerutti JM. Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol 2010, 163: 747–55.
Lindsey SC, Kunii IS, Germano-Neto F, et al. Extended RET gene analysis in patients with apparently sporadic medullary thyroid cancer: clinical benefits and cost. Horm Cancer 2010, 3: 181–6.
Oler G, Nakabashi CD, Biscolla RP, Cerutti JM. Seven-year follow-up of a juvenile female with papillary thyroid carcinoma with poor outcome, BRAF mutation and loss of expression of iodine-metabolizing genes. Arq Bras Endocrinol Metabol 2008, 52: 1313–6.
Cerutti JM, Oler G, Michaluart P jr, et al. Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer Res 2007, 67: 7885–92.
Oliveira MN, Hemerly JP, Bastos AU, et al. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia Type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo. Thyroid 2011, 21: 975–85.
Qi XP, Ma JM, Du ZF, et al. RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family. PLoS One 2011, 6: e20353.
Conzo G, Circelli L, Pasquali D, et al. Lessons to be learned from the clinical management of a MEN 2A patient bearing a novel 634/640/700 mutation of the RET proto-oncogene. Clin Endocrinol 2012, 77: 934–6.
Pompanon F, Bonin A, Bellemain E, Taberlet P. Genotyping errors: causes, consequences and solutions. Nat Rev Genet 2005, 6: 847–59.
Magalhaes PK, de Castro M, Elias LL, Soares EG, Maciel LM. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma. Thyroid 2004, 14: 848–52.
Guerrero IM, Pessoa CH, Olmedo DB, et al. Analysis of inherited genetic variants in ret proto-oncogene of Brazilian patients with apparently sporadic medullary thyroid carcinoma. Thyroid 2006, 16: 9–15.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Valente, F.O.F., da Silva, M.R.D., Camacho, C.P. et al. Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: An appraisal of p.Y791 F and p.C634Y RET mutations in five unrelated Brazilian families. J Endocrinol Invest 36, 975–981 (2013). https://doi.org/10.3275/8997
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3275/8997